Bryce Point Capital LLC Takes $1.78 Million Position in Sotera Health (NASDAQ:SHC)

Bryce Point Capital LLC purchased a new stake in shares of Sotera Health (NASDAQ:SHC) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 130,424 shares of the company’s stock, valued at approximately $1,784,000. Sotera Health comprises 0.5% of Bryce Point Capital LLC’s portfolio, making the stock its 26th biggest position.

Other hedge funds have also bought and sold shares of the company. Norges Bank purchased a new position in Sotera Health in the fourth quarter valued at about $12,764,000. State Street Corp raised its holdings in shares of Sotera Health by 18.5% in the 3rd quarter. State Street Corp now owns 4,126,806 shares of the company’s stock worth $68,918,000 after purchasing an additional 644,236 shares during the period. Bank of New York Mellon Corp lifted its stake in Sotera Health by 45.1% in the fourth quarter. Bank of New York Mellon Corp now owns 1,630,736 shares of the company’s stock valued at $22,308,000 after purchasing an additional 507,147 shares during the last quarter. Geode Capital Management LLC grew its holdings in Sotera Health by 19.4% during the third quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock valued at $46,026,000 after purchasing an additional 447,186 shares during the period. Finally, Barclays PLC increased its position in Sotera Health by 169.8% in the third quarter. Barclays PLC now owns 473,597 shares of the company’s stock worth $7,909,000 after buying an additional 298,085 shares during the last quarter. 91.03% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SHC has been the topic of a number of recent research reports. The Goldman Sachs Group began coverage on Sotera Health in a research report on Friday, December 6th. They set a “neutral” rating and a $14.00 price target on the stock. Barclays dropped their price objective on shares of Sotera Health from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Sotera Health Stock Performance

NASDAQ:SHC opened at $11.13 on Wednesday. The business’s fifty day moving average is $12.77 and its 200 day moving average is $13.91. The firm has a market cap of $3.16 billion, a price-to-earnings ratio of 44.52 and a beta of 1.92. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.08.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.